. Author manuscript; available in PMC: 2013 Nov 7.

Published in final edited form as: Curr Pharm Des. 2012;18(9):1217–1239. doi: 10.2174/138161212799436386

Table 4.

Recent development in drug development starting from homology modeling

Target	Indication	Inhibitor	Reference
Renin	Hypertension	Aliskiren (Tekturna^®)	[235]
EtCRK2	Avian coccidiosis	BES062021, BES143551, BES241415, BES252034	[238]
Dynamin receptor	Epileptic seizures	Pthaladyn scaffold	[237]
hIKK-2	Chronic inflammatory diseases	ZINC03871389	[239]
Cdc25A	Cancer	1-phenyl-2-(5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)ethanone scaffold	[240]
α-glucosidase	Diabetes	13 inhibitors (< IC₅₀ 50μM)	[241]
PH domain leucine-rich protein phosphatase	Diabetes, heart disease	NCS45586, NCS117079	[242]
NF-κB inducing kinase	Rheumatoid arthritis	4H-isoquinoline-1,3-dione scaffold	[243]
Matriptase-2	Iron homeostasis, breast/prostate cancer	Three N-protected dipeptide amides conjugated to 4-amidinobenzylamide	[244]
Chemokine receptor -2 (CCR2)	Anti-inflammation	G365-0350	[245]